Atea Pharmaceuticals (AVIR) CDO reports RSU vesting, 177,000-share option

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Atea Pharmaceuticals Chief Development Officer Janet Hammond reported multiple equity award transactions. On January 31, 2026, 58,050 shares of common stock were acquired through RSU conversions, with 14,136 shares withheld at $4.24 per share to cover taxes, leaving 127,665 common shares directly held.

Concurrent with this, 46,800 RSUs from a 140,400-unit grant that fully vested by January 31, 2026, and 11,250 performance-based RSUs were settled into common stock, reducing RSU holdings to zero. Hammond also received a stock option for 177,000 shares at an exercise price of $4.24 per share, vesting in 48 equal monthly installments after January 31, 2026, and fully vesting on January 31, 2030.

Insider Trade Summary

58,050 shares exercised/converted

Mixed 5 txns

Insider Hammond Janet MJ

Role Chief Development Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	46,800	$0.00	--
Exercise	Restricted Stock Units	11,250	$0.00	--
Grant/Award	Stock Option (Right to Buy)	177,000	$0.00	--
Exercise	Common Stock	58,050	$0.00	--
Tax Withholding	Common Stock	14,136	$4.24	$60K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Stock Option (Right to Buy) — 177,000 shares (Direct); Common Stock — 141,801 shares (Direct)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Includes 2,363 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. The original grant of 140,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Form 4 Insider Transactions: What Each Field Means →

02/03/2026 - 07:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hammond Janet MJ

(Last)

(First)

(Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON

02110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/31/2026		M		58,050	A	⁽¹⁾	141,801⁽²⁾	D
Common Stock	01/31/2026		F		14,136	D	$4.24	127,665	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/31/2026		M			46,800	⁽³⁾	⁽³⁾	Common Stock	46,800	$0	0	D
Restricted Stock Units	⁽¹⁾	01/31/2026		M			11,250	⁽⁴⁾	⁽⁴⁾	Common Stock	11,250	$0	0	D
Stock Option (Right to Buy)	$4.24	01/31/2026		A		177,000		⁽⁵⁾	01/30/2036	Common Stock	177,000	$0	177,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. Includes 2,363 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

3. The original grant of 140,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

4. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

5. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Janet Hammond	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Atea Pharmaceuticals (AVIR) report for Janet Hammond?

Janet Hammond reported RSU settlements into common stock and a new stock option grant. She acquired 58,050 common shares via RSU conversions and was granted options for 177,000 shares, alongside tax withholding and performance-based RSU vesting activity.

How many Atea Pharmaceuticals (AVIR) shares does Janet Hammond hold after the reported Form 4?

After the transactions, Janet Hammond directly holds 127,665 shares of Atea Pharmaceuticals common stock. This figure reflects RSU conversions into shares and share withholding for taxes, as disclosed, and represents her post-transaction direct common stock ownership.

What RSU activity did Atea Pharmaceuticals (AVIR) disclose for Janet Hammond?

The filing shows 46,800 RSUs from a 140,400-unit grant and 11,250 performance-based RSUs were converted into common stock on January 31, 2026. Following these settlements, Hammond held zero RSUs, with each RSU representing one share of common stock.

What are the terms of Janet Hammond’s new stock option at Atea Pharmaceuticals (AVIR)?

Hammond received a stock option to buy 177,000 Atea common shares at an exercise price of $4.24 per share. The option vests in 48 equal monthly installments after January 31, 2026 and becomes fully vested on January 31, 2030, expiring January 30, 2036.

Why were some Atea Pharmaceuticals (AVIR) shares withheld in Janet Hammond’s Form 4?

The filing reports 14,136 common shares were disposed of at $4.24 per share under transaction code “F.” This code indicates shares were withheld to satisfy tax obligations associated with the RSU vesting and conversion into common stock.

What does the RSU vesting schedule indicate for Atea Pharmaceuticals (AVIR) equity awards?

A prior grant of 140,400 RSUs vested in three equal annual installments on the first three anniversaries of January 31, 2023. This schedule meant all RSUs from that grant were fully vested as of January 31, 2026, when a portion was settled into common stock.